A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
Status:
Completed
Trial end date:
2019-01-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine whether ACH-0144471 (also known as
danicopan and ALXN2040) increases blood C3 complement protein (C3) levels in participants
with low C3 levels due to either C3G or IC-MPGN.